Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Appili Therapeutics Inc (OP: APLIF )

0.0277 +0.0024 (+9.49%)
Streaming Delayed Price Updated: 11:27 AM EST, Nov 4, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Appili Therapeutics Inc

< Previous 1 2 Next >
Appili Therapeutics Announces Issuance of Patent for ATI-1501 Liquid Oral Reformulation of Metronidazole
From Appili Therapeutics Inc.
Via Business Wire
Appili Therapeutics to Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference
From Appili Therapeutics Inc.
Via Business Wire
Appili Therapeutics Appoints Dr. Gary Nabors as Chief Development Officer
From Appili Therapeutics Inc.
Via Business Wire
Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2023
From Appili Therapeutics Inc.
Via Business Wire
Appili Therapeutics Appoints Dr. Carl Gelhaus and Arthur Baran to support the ATI-1701 Biodefense Vaccine Program
From Appili Therapeutics Inc.
Via Business Wire
Appili Therapeutics Announces Notice of Allowance from the U.S. Patent and Trademark Office for ATI-1501 Liquid Oral Reformulation of Metronidazole
From Appili Therapeutics Inc.
Via Business Wire
Appili Therapeutics ATI-1701 Biodefense Vaccine Secures ~US$14 Million of Funding from the U.S. Department of Defense in Partnership with the U.S. Air Force Academy
From Appili Therapeutics Inc.
Via Business Wire
Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2023
From Appili Therapeutics Inc.
Via Business Wire
Appili Therapeutics Announces Results of Annual and Special Meeting of Shareholders
From Appili Therapeutics Inc.
Via Business Wire
Appili Therapeutics Reports Financial and Operational Results for First Quarter of Fiscal Year 2023
From Appili Therapeutics Inc.
Via Business Wire
Appili Therapeutics to Present at WorldLeish7 Conference in Cartagena, Columbia
From Appili Therapeutics Inc.
Via Business Wire
Appili Therapeutics Reports Fiscal Year 2022 Financial and Operational Results
From Appili Therapeutics Inc.
Via Business Wire
Appili Therapeutics to Present at the 2022 Bloom Burton & Co. Healthcare Investor Conference
From Appili Therapeutics Inc.
Via Business Wire
Appili Therapeutics Announces New Late-Stage Clinical Program ATI-1801 to Treat Cutaneous Leishmaniasis
From Appili Therapeutics Inc.
Via Business Wire
Appili Therapeutics Announces Over US$10 Million in New Funding from US Department of Defense for Biodefense Vaccine Candidate ATI-1701
From Appili Therapeutics Inc.
Via Business Wire
Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2022
From Appili Therapeutics Inc.
Via Business Wire
Appili Therapeutics Expands ATI-1501 Commercial Agreement with Partner Saptalis Pharmaceuticals
From Appili Therapeutics Inc.
Via Business Wire
Appili Therapeutics Announces Positive One Year Challenge Results from Preclinical Study Evaluating Biodefense Vaccine Candidate ATI-1701 and Change to Board of Directors
From Appili Therapeutics Inc.
Via Business Wire
Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2022 and Change of Chief Financial Officer
From Appili Therapeutics Inc.
Via Business Wire
Appili Therapeutics Provides Update on Phase 3 PRESECO Clinical Trial Evaluating Avigan®/Reeqonus™
From Appili Therapeutics Inc.
Via Business Wire
Aditxt Shares Surge On AiPharma Acquisition, Holder Of COVID-19 Candidate
Aditxt Inc (NASDAQ: ADTX) has agreed to acquire AiPharma Global Holdings LLC, focused on discovering, developing, and commercializing antiviral therapies. AiPharma... 
Via Benzinga
Exposures COVID-19
Appili Therapeutics and AiPharma Announce Strategic Alliance and Equity Transaction
From Appili Therapeutics Inc.
Via Business Wire
Appili Therapeutics Announces Last Patient Enrolled in Phase 3 Trial of Oral Avigan®/Reeqonus™ for the Treatment of Mild-to-Moderate COVID-19
From Appili Therapeutics Inc.
Via Business Wire
Appili Therapeutics Announces Agreement with FUJIFILM and Funding Support for Clinical Trial Program Evaluating Avigan®/Reeqonus™ for COVID-19 Patients
From Appili Therapeutics Inc.
Via Business Wire
Appili Therapeutics Announces Completion of Patient Enrollment for Avigan®/Reeqonus™ Viral Shedding Sub- Study for Mild-to-Moderate COVID-19 Patients
From Appili Therapeutics Inc.
Via Business Wire
Appili Therapeutics Announces Results for Resolutions at Annual General Meeting of Shareholders
From Appili Therapeutics Inc.
Via Business Wire
Appili Therapeutics Reports Financial and Operational Results for First Quarter of Fiscal Year 2022
From Appili Therapeutics Inc.
Via Business Wire
Appili Therapeutics Reports Fiscal Year 2021 Financial and Operational Results and Provides Update on Strategy for Fiscal 2022
From Appili Therapeutics Inc.
Via Business Wire
Appili Therapeutics Inc. Expands PRESECO Clinical Trial of Avigan®/Reeqonus™ for Mild-to-Moderate COVID-19 Patients into Mexico and Brazil
From Appili Therapeutics Inc.
Via Business Wire
Appili Therapeutics to Present at the Bloom Burton & Co. Healthcare Investor Virtual Conference on Wednesday, April 21st, 2021
From Appili Therapeutics Inc.
Via Business Wire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.